Knee OsteoarthristisNCT07089446
Combination of Platelets Rich Plasma and Hyaluronic is an Effective Tool for Treatment of Knee Osteoarthritis
A study testing Hyaluronic Acid (HA), Platelet Rich Plasma and Hyaluronic Acid (HA) and Platelet rich plasma in people with Knee Osteoarthristis, run by University of Karachi at 1 site in Pakistan.
Trial summary
The purpose of the study is to determine the effects of HA, PRP and the combination of HA and PRP in reducing pain and improving functional disability in patients with knee osteoarthritis. Read more about this study
- Who is it for?
- Ages 40 to 70 years
- Conditions the study is for
- Knee Osteoarthristis
- What is being tested?
- Hyaluronic Acid (HA), Platelet Rich Plasma and Hyaluronic Acid (HA) and Platelet rich plasma
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 sitePakistan
- Study dates
- 21 Sep 2022to 15 Jun 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- grade II-III according to the Kellgren-Lawrence classification),
- pain or functional limitations in patients' activity of daily living before the treatment,
- age between 40 and 70 years of age, and the absence of clinical or imaging signs of articular instability.
Who cannot join
- includes known hypersensitivity to hyaluronic acid,
- pregnancy and lactation, a BMI greater than 40 kg/m2,
- chronic administration of anticoagulant drugs or a history of coagulopathies,
- neoplastic lesions, and knee or kidney failures
Trial locations and contacts
1 site in 1 country.
About this study
The purpose of the study is to determine the effects of HA, PRP and the combination of HA and PRP in reducing pain and improving functional disability in patients with knee osteoarthritis.
Read the detailed description
To determine the effects of combination of platelet rich plasma (PRP) and hyaluronic acid and the PRP or HA alone in reducing pain and increasing range of motion among individuals with knee osteoarthritis.
- Conditions
- Knee Osteoarthristis
- Being tested
- Hyaluronic Acid (HA), Platelet Rich Plasma, Hyaluronic Acid (HA) and Platelet rich plasma
- Keywords
- Hyaluronic acid, osteoarthritis, pain, disability
- Medical subject headings
- Osteoarthritis, Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hyaluronic Acid (HA)Drug
Hyaluronic Acid
Platelet Rich PlasmaDrug
Platelet rich plasma
Hyaluronic Acid (HA) and Platelet rich plasmaDrug
Hyaluronic Acid and Platelet rich plasma
| Study group | Role | What they receive |
|---|---|---|
| Group A | Experimental | Hyaluronic acid Receives: Drug: Hyaluronic Acid (HA) |
| Group B | Active comparator | platelet rich plasma Receives: Drug: Platelet Rich Plasma |
| Group C | Other | Hyaluronic acid and platelet rich plasma Receives: Drug: Hyaluronic Acid (HA) and Platelet rich plasma |
What is being measured
The primary outcome is the main question the study is designed to answer.
visual analogue scale
It is a straight line, 100 millimeters long line, one end of the line means "not at all" or "none" and the other end means "the worst possible" or "extremely".
Measured: Recorded before the treatment and repeated within 3 and 6 months after the treatment.
Secondary outcomes (1)
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
It s a questionnaire used to assess pain, stiffness, and physical function in individuals with osteoarthritis, particularly of the knee. It is a self-administered, multidimensional tool that evaluates these three dimensions through a series of questions, typically on a Likert scale.
Measured: Recorded before the treatment and repeated within 3 and 6 months after the treatment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2025
- Study start21 Sep 2022
- Primary completion2 May 2025
- Study completion15 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Knee OsteoarthristisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants were randomly divided into three groups. Twenty cases (Group A) were injected with HA, 20 (Group B) had PRP, and the remaining 20 (Group C) received a combination of HA and PRP
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Karachi
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr Ranjeet Kumar, University of Karachi
- Investigators
- Basit Ansari, PhD, Study chair, University of KarachiRanjeet Kumar, MBBS, FCPS, Principal investigator, University of KarachiAftab Ahmed Mirza Baig, PhD, Study director, IQRA University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07089446
- Sponsor's protocol ID
- SCH-IRB-2022-05
- Status last verified
- Jul 2025
- First submitted
- 20 Jul 2025
- Last updated
- 28 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Combination of Platelets Rich Plasma and Hyaluronic is an Effective Tool for Treatment of Knee Osteoarthritis
- ClinicalTrials.gov ID
- NCT07089446
- Acronym / sponsor ID
- SCH-IRB-2022-05
- Conditions
- Knee Osteoarthristis
- Keywords
- Hyaluronic acid, osteoarthritis, pain, disability
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- University of KarachiUniversity, hospital or other
- Study start
- 21 Sep 2022 (actual)
- Primary completion
- 2 May 2025 (actual)
- Study completion
- 15 Jun 2025 (actual)
- First posted
- 28 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to determine the effects of HA, PRP and the combination of HA and PRP in reducing pain and improving functional disability in patients with knee osteoarthritis.
Detailed description
To determine the effects of combination of platelet rich plasma (PRP) and hyaluronic acid and the PRP or HA alone in reducing pain and increasing range of motion among individuals with knee osteoarthritis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
- Model description
- Participants were randomly divided into three groups. Twenty cases (Group A) were injected with HA, 20 (Group B) had PRP, and the remaining 20 (Group C) received a combination of HA and PRP
| Arm | Type | Receives |
|---|---|---|
| Group A | Experimental | Drug: Hyaluronic Acid (HA)Hyaluronic acid |
| Group B | Active comparator | Drug: Platelet Rich Plasmaplatelet rich plasma |
| Group C | Other | Drug: Hyaluronic Acid (HA) and Platelet rich plasmaHyaluronic acid and platelet rich plasma |
Who may qualify
- Ages
- 40 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- grade II-III according to the Kellgren-Lawrence classification),
- pain or functional limitations in patients' activity of daily living before the treatment,
- age between 40 and 70 years of age, and the absence of clinical or imaging signs of articular instability.
Key exclusion criteria (4 listed)
- includes known hypersensitivity to hyaluronic acid,
- pregnancy and lactation, a BMI greater than 40 kg/m2,
- chronic administration of anticoagulant drugs or a history of coagulopathies,
- neoplastic lesions, and knee or kidney failures
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hyaluronic Acid (HA)Hyaluronic Acid | Drug | Group A |
| Platelet Rich PlasmaPlatelet rich plasma | Drug | Group B |
| Hyaluronic Acid (HA) and Platelet rich plasmaHyaluronic Acid and Platelet rich plasma | Drug | Group C |
Primary outcome
visual analogue scale
Time frame: Recorded before the treatment and repeated within 3 and 6 months after the treatment.
It is a straight line, 100 millimeters long line, one end of the line means "not at all" or "none" and the other end means "the worst possible" or "extremely".
1 secondary outcome
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Time frame: Recorded before the treatment and repeated within 3 and 6 months after the treatment.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jul 2025.
Related trials for Knee Osteoarthristis
Recruiting
Aquatic Exercise in Patients With Knee Osteoarthritis
Central Sensitization, Knee Osteoarthristis
Recruiting
Study NRPT Feasibility in Knee Osteoarthritis
Knee Osteoarthristis
Not yet recruitingEarly Phase 1
Medication vs. Meditation for Chronic Knee Osteoarthritis
Knee Osteoarthristis
Not yet recruiting
Wearable Device Guided Exercise for Patients on Total Knee Arthroplasty Wait-list
Knee Osteoarthristis
Not yet recruiting
Application of Perinatal Derivatives in Total Knee Arthroplasty
Total Knee Arthroplasty, Knee Osteoarthristis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Basit Ansari, PhD study chair
University of Karachi
Ranjeet Kumar, MBBS, FCPS principal investigator
University of Karachi
Aftab Ahmed Mirza Baig, PhD study director
IQRA University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Hyaluronic Acid (HA), Platelet Rich Plasma and Hyaluronic Acid (HA) and Platelet rich plasma in people with Knee Osteoarthristis, run by University of Karachi at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
visual analogue scale (time frame: Recorded before the treatment and repeated within 3 and 6 months after the treatment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2025.